Product image of Maxalt (Rizatriptan Benzoate) supplied by GNH India

Maxalt

Active Ingredient:
Rizatriptan Benzoate
Origin:
EU

Maxalt (Rizatriptan Benzoate)

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as an oral tablet for oral administration. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients who require rapid symptom relief and can be used at the first sign of headache.
GNH India supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across multiple regions. We adhere to stringent import standards.

Manufacturer / TM Owner

N.V. Organon

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Rizatriptan, a Triptan acting on serotonin receptors, is used for migraine management.
  • Migraine with aura: provides rapid relief of headache and associated symptoms.
  • Migraine without aura: aborts attacks and reduces need for additional medication.
  • Acute migraine episodes: can be taken at the first sign of headache to stop progression.
  • Adults only: recommended for patients 18 years and older.
  • Patients with contraindications to ergotamines: offers an alternative mechanism of action.
  • Rapid onset: typically begins working within 30 minutes after ingestion.
  • Improves functional ability: enables patients to resume normal activities sooner.

How It Works

  • Rizatriptan selectively binds to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. Activation of these receptors causes vasoconstriction of dilated intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the migraine cascade and providing rapid headache relief.

Side Effects

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Chest discomfort or tightness
  • Tingling or numbness in fingers or toes
  • Nausea or abdominal pain
  • Dizziness or light‑headedness
  • Dry mouth
  • Fatigue

Serious or Rare Side Effects

  • Serotonin syndrome, especially with serotonergic drugs
  • Cardiac ischemia or arrhythmia in susceptible patients
  • Severe allergic reaction (anaphylaxis)
  • Persistent visual disturbances
  • Severe hypertension
  • Pulmonary edema

Precautions & Warnings

  • Before prescribing Rizatriptan, clinicians should evaluate patient‑specific risk factors and comorbidities.
  • Assess cardiovascular risk: review history of coronary artery disease, hypertension, or stroke.
  • Avoid in uncontrolled hypertension: ensure blood pressure is well‑controlled before use.
  • Screen for drug interactions: check concomitant serotonergic agents that may increase serotonin syndrome risk.
  • Pregnancy and lactation: consider limited safety data and weigh benefits against potential risks.
  • Store at ambient temperature: keep tablets below 25°C in the original container, protected from moisture and light.

Avoid Interactions

Rizatriptan can interact with several medication classes; careful review is essential.

Major Interactions (Avoid)

  • MAO inhibitors: combined use may precipitate serotonin syndrome.
  • Other triptans or ergotamine derivatives: additive vasoconstriction risk.
  • SSRIs, SNRIs, or other serotonergic agents: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise rizatriptan plasma levels.
  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness.
  • Certain antihypertensives: monitor blood pressure response.

Frequently Asked Questions

Maxalt contains rizatriptan, which is prescribed for the acute treatment of migraine attacks, with or without aura, in adult patients. It works to relieve headache pain and associated migraine symptoms when taken at the onset of an attack.

Rizatriptan selectively activates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This activation causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade.

The dosage of Maxalt is individualized by the prescribing healthcare professional based on the patient’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for rizatriptan in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Maxalt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxalt belongs to the triptan class, which provides rapid migraine relief by targeting serotonin receptors. Compared with ergotamine derivatives, triptans like rizatriptan have a more specific mechanism, fewer vascular side effects, and are generally better tolerated, though individual response may vary.

Store Maxalt tablets at ambient temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Maxalt is taken orally as a tablet. The patient should swallow the tablet whole with water, preferably at the first sign of a migraine attack. If needed, a second dose may be taken after a minimum interval as directed by the prescriber.

Serious risks include serotonin syndrome, especially when combined with other serotonergic drugs, and cardiovascular events such as chest pain, coronary artery spasm, or arrhythmias in patients with underlying heart disease. Any severe or unexpected symptoms should prompt immediate medical attention.

Maxalt should be avoided in patients with known hypersensitivity to rizatriptan, uncontrolled hypertension, significant cardiovascular disease (e.g., recent myocardial infarction, severe coronary artery disease), or in those taking monoamine oxidase inhibitors within the past 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.